Translational Research

Welcome to the NINDS Division of Translational Research (DTR). Our mission is to accelerate the preclinical discovery and development of new therapeutic interventions for neurological disorders.  DTR helps academic and industry researchers create a bridge through which discoveries made in the lab lead to new and improved medical treatments and options for patient care.  To facilitate this process, DTR provides many funding opportunities to accelerate leading-edge preclinical research and technology for neurological disorders. 

DTR provides funding and resources (approximately $100 million annually) through grants, cooperative agreements, and contracts to academic and industry researchers to advance early-stage neurological technologies, devices, and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships).  DTR offers a variety of programs that support the design, implementation, and management of research activities critical to translational challenges in the treatment of neurological disease.

For investigators and potential investors interested in our active grant portfolio or in partnering.

For investigators and potential investors interested in our active grant portfolio or in partnering.

An overview of the public health impact the Grantees have had for research on brain and nervous system disorders.

tr-dt-icon-alt

Are you new to Translational Research?

Check out our to explore funding opportunity pathways.

A suite of funding opportunity announcements to enable grantees to build on their innovative basic science findings and initiate preclinical drug discovery and development.

Resources for compound-screening service to identify candidate therapeutics to ameliorate the epilepsies. Current efforts emphasize unmet medical needs in epilepsy, including treatments for refractory epilepsies, epileptogenesis, and disease progression.

Cooperative agreement and SBIR Fast-Track award programs support small molecule drug discovery and development.  These programs are designed to maintain the grantees’ intellectual property while providing non-dilutive funding. 

Cooperative agreement and SBIR Fast-Track award programs support the discovery and development of therapeutic Biotechnology Products and Biologics (e.g. peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission. 

Contact: Stephanie Fertig, MBA
Funding to support development, validation and verification, and early clinical studies of therapeutic devices to treat neurological disorders. 

Funding program to allow small business concerns to conduct innovative neuroscience research at different stages of development, including applied bench research, translational research, and early-stage clinical trials.

The mission of the NIH CounterACT Program is to understand fundamental mechanisms of toxicity caused by chemical threat agents and the application of this knowledge to develop promising therapeutics for reducing mortality and morbidity caused by these agents. CounterACT is a trans-NIH effort lead by NINDS which funds small and large grants, supportive contract facilities, and interagency agreements with the Department of Defense.

Short course to introduce academic researchers to the principles of neurotherapeutic drug discovery and development.  Participants who have attended the short course program will have ongoing access to senior faculty who will assist the trainee to achieve success in their individual drug development projects. 

The BrIDGs program assists researchers in advancing promising therapeutic agents through late-stage pre-clinical development toward an Investigational New Drug (IND) application and clinical testing. Investigators do not receive grant funds through this program. Instead, selected researchers partner with NCATS experts to generate pre-clinical data and clinical-grade material through government contracts for use in IND applications. 

The TRND program supports pre-clinical development of therapeutic candidates intended to treat rare or neglected disorders, with the goal of enabling an Investigational New Drug (IND) application.  The objective is to “de-risk” therapeutic development efforts and facilitate collaborations by outside business partners to bring these treatments to patients.